Tivorsan was co-founded by Dr. Justin Fallon, Professor of Neuroscience at Brown University, to develop biglycan as a therapy for Duchenne. Charley’s Fund was an early supporter of Dr. Fallon’s work, and we are founding shareholders in Tivorsan. The company is moving ahead with an aggressive timeline to get biglycan into the clinic.
Retrophin is an emerging biotechnology company focused on rare and life-threatening diseases. Retrophin’s lead compound, RE-001, is based on a therapeutic approach that was conceived of and developed by Dr. James Ervasti at the University of Minnesota. With support from Charley’s Fund and the Nash Avery Foundation, Dr. Ervasti conducted crucial animal studies that demonstrated [...]